Promising drug targets Hard-to-Treat breast cancer in chinese patients

NCT ID NCT04454437

Ongoing Disease control Sponsor: Gilead Sciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called sacituzumab govitecan in 80 Chinese patients with metastatic triple-negative breast cancer who have already tried at least two other treatments. The goal is to see if the drug can shrink tumors or slow the disease. Participants receive the drug intravenously, and researchers track how many respond and for how long.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC TRIPLE-NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC TRIPLE-NEGATIVE BREAST CANCER

Contacts and locations

Locations

Anhui Provincial Hospital

Hefei, 230001, China
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, 100021, China
Chinese PLA General Hospital

Beijing, 100853, China
Chongqing University Cancer Hospital

Chongqing, 404100, China
Hubei Cancer Hospital

Wuhan, 430000, China
Hunan Cancer Hospital

Changsha, 410013, China
Liaoning Cancer Hospital & Institute

Shenyang, Liaoning, China
Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine

Hangzhou, Zhejiang, China
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University

Guangzhou, 510120, China
Sun Yat-sen University, Cancer Center

Guangzhou, 510000, China
The First Affiliated Hospital of Anhui Medical University

Hefei, 230022, China
The First Affiliated Hospital of Xi'an Jiaotong University

Xi'an, 710061, China
The First Hospital of China Medical University

Shenyang, 110001, China
The First Hospital of Jilin University

Changchun, 130021, China
Tianjin Medical University Cancer Institute & Hospital

Tianjin, 300060, China
West China Hospital, Sichuan University

Chengdu, China
Zhejiang Cancer Hospital

Hangzhou, 310022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.